7 Dec 2017
New state-of-the-art equipment for the production of drug-loaded monodispersed biodegradable particles
Dr Goran Vladisavljevic’s microfluidic group has received a capital investment from Med Alliance Group, Inc., a Switzerland-based medical device company, in the amount of over £42,000 for the purchase of the Dolomite’s state-of-the-art Telos® high-throughput droplet microfluidic platform. The system will be installed in the Department of Chemical Engineering and used for the production of drug-loaded monodispersed biodegradable particles. The technology will be developed within a PhD studentship awarded to Dr Goran Vladisavljevic and Dr Guido Bolognesi from the National Productivity Investment Fund (NPIF).
The Telos® System is a breakthrough microfluidic platform for high-throughput droplet generation and micro-particle production. This modular, scalable, and highly flexible system removes the low throughput limitation of individual microfluidic chips, enabling litres of droplets or particles to be produced in a day. Up to 10 Telos® modules can be assembled in parallel. Each module holds a microfluidic chip with 7 junctions, enabling a total of 70 parallel 3D flow-focusing junctions to be run at once. All junctions are visible from above and below enabling monitoring and recording of drop generation in real time.